Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.62 |
| ▸ | CDC7 | O00311 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28421264 | 0.82 | CDC7 (0.50) | PARP3CDC7CYP3A4HTR2BCA12 | |
| SCHEMBL5008096 | 0.78 | PARP1 (0.50) | PARP3CDC7MEN1CYP3A4CYP2D6 | |
| SCHEMBL29921579 | 0.74 | CDC7 (0.46) | PARP3CDC7MEN1CYP3A4CYP2D6 | |
| SCHEMBL21187107 | 0.74 | PARP3 (0.53) | PARP3HTR2AHTR2CHTR2BALDH1A1 | |
| SCHEMBL11750196 | 0.74 | PARP3 (0.61) | PARP3HTR2AHTR2CHTR2BCA12 | |
| SCHEMBL12220005 | 0.74 | PARP3 (0.53) | PARP3CDC7HTR2AHTR2CHTR2B | |
| SCHEMBL6635520 | 0.74 | PARP3 (0.53) | PARP3CDC7HTR2AHTR2CHTR2B | |
| SCHEMBL29594704 | 0.74 | PARP3 (0.56) | PARP3HTR2AHTR2CHTR2BALDH1A1 | |
| SCHEMBL2098364 | 0.74 | PARP3 (0.56) | PARP3HTR2AHTR2CHTR2BALDH1A1 | |
| SCHEMBL11428129 | 0.73 | CDC7 (0.40) | PARP3CDC7MEN1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809538-B2 | Piperidine-containing compounds and use thereof | ARRAY BIOPHARMA INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20110275608-A1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-11-10 | — | — | US | disclosed |
| EP-2375899-A1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF | Array Biopharma, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010080864-A1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| CN-1131216-C | Condensed 1, 2-indanes and their pharmaceutically acceptable salts, process for their preparation and their use | TAIHO PHARMACEUTICAL CO LTD (JP) | 2003-12-17 | — | — | CN | disclosed |
| US-6127372-A | FOR TREATMENT OR PREVENTION OF VIRAL DISEASES, ESPECIALLY AIDS OR HIV | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2000-10-03 | — | — | US | disclosed |
| EP-0749421-B1 | SULPHONAMIDE DERIVATIVES AS ASPARTYL PROTEASE INHIBITORS | VERTEX PHARMA (US) | 1999-09-15 | — | — | EP | disclosed |
| EP-0749421-A1 | SULPHONAMIDE DERIVATIVES AS ASPARTYL PROTEASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 1996-12-27 | — | — | EP | disclosed |
| CN-1130903-A | Condensed 1,2-indene dihydride and its salt for medicine | TAIHO PHARMACEUTICAL CO LTD (JP) | 1996-09-11 | — | — | CN | disclosed |
| WO-1995024385-A1 | SULPHONAMIDE DERIVATIVES AS ASPARTYL PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1995-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275608-A1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF | NOS1, NOS2, ASS1 | PARP3 3997/4885CDC7 4618/4885MEN1 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.